The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD005231 and the list of peptides can be found in S1 Dataset. The code to predict HLA-I ligands can be accessed at <https://github.com/GfellerLab/MixMHCpred> (version 1.0).

Introduction {#sec001}
============

HLA-I molecules play a central role in defence mechanisms against pathogens and immune recognition of cancer cells. Their main functionality is to bind short peptides (mainly 9- to 12-mers) coming from degradation products of endogenous or viral proteins. The peptides are cleaved in the proteasome, transported by the transporter associated with antigen processing (TAP) complex, loaded onto the HLA-I molecules in the ER and presented at the cell surface \[[@pcbi.1005725.ref001]\]. Non-self peptides presented on HLA-I molecules, such as those derived from degradation of viral proteins, mutated proteins (referred to as neo-antigens), and other cancer specific and abnormally expressed proteins can then be recognized by CD8 T cells and elicit cytolytic activity. Neo-antigens have recently emerged as promising targets for development of personalized cancer immunotherapy \[[@pcbi.1005725.ref002]\].

Human cells express three HLA-I genes (HLA-A/B/C). These genes are the most polymorphic of the human genome and currently more than 12,000 different alleles have been observed \[[@pcbi.1005725.ref003]\]. Such a high polymorphism makes it challenging to model the different binding specificities of each allele and predict antigens presented at the cell surface. Information about binding motifs (mathematically defined here as Position Weight Matrices and graphically represented as sequence logos) of HLA-I molecules has been mainly obtained from biochemical assays where chemically synthesized peptides are tested *in vitro* for binding. This *in vitro* approach is experimentally laborious, time consuming and expensive. Currently, the most frequent HLA-I alleles have thousands of known ligands that provide a detailed description of their binding specificity. Many of these ligands are stored in very important resources such as IEDB \[[@pcbi.1005725.ref004],[@pcbi.1005725.ref005]\] and have been used to train machine learning algorithms for HLA-I ligand predictions \[[@pcbi.1005725.ref006]--[@pcbi.1005725.ref011]\]. As a result, for frequent alleles in Caucasian populations, much is known about their binding specificity. However, the vast majority (\>95%) of HLA-I alleles still lack documented ligands and despite very valuable algorithmic developments to generalize prediction methods to any allele \[[@pcbi.1005725.ref012]\], it remains more challenging to make accurate predictions for alleles without known ligands. Importantly, although these alleles are only found in a small fraction of the Caucasian population, they are more frequently encountered in other ethnic groups and gaining more understanding of their binding specificity would be desirable for expanding the scope of therapeutic strategies relying on HLA-I ligand predictions. Moreover, many alleles with known motifs are supported by only a few tens of peptides and some of these ligands have been selected based on *a priori* expectations of the binding specificity rather than unbiased screening of random peptide libraries. Such potentially biased datasets can be sub-optimal for training HLA-I ligand predictors.

Mass-spectrometry (MS) analysis of HLA-I binding peptides eluted from cell lines or tissue samples is a promising alternative to the use of HLA-I ligand interaction predictions \[[@pcbi.1005725.ref013]\] and MS is increasingly used to directly identify viral \[[@pcbi.1005725.ref014],[@pcbi.1005725.ref015]\] or cancer-specific (neo-)antigens \[[@pcbi.1005725.ref013],[@pcbi.1005725.ref016]--[@pcbi.1005725.ref020]\]. For neo-antigen discovery, tumor exome sequencing is first performed. Patient-specific non-synonymous somatic alterations are included in a customized database. MS-MS spectra of HLA ligands eluted from the patient's tissue samples are searched against this expanded database permitting either the wild-type or the mutated peptide sequences to be identified. Neo-antigens directly identified this way, or alternatively predicted in-silico, may be further validated using targeted mass-spectrometry approaches in which isotopically heavy-labeled synthetic peptides are spiked into the HLA ligands eluted from the patient's tumor tissue. Identification of co-eluting pairs of heavy (standard) and light (endogenous) peptides validate the presentation of the neo-antigen in the investigated tissue \[[@pcbi.1005725.ref019]\]. However, this technique is only applicable to a small fraction of samples due to the large amount of material that is required for MS analysis (typically 1cm^3^ of tissue material, or 1x10^8^ cells in culture) and the complexity of these experiments.

In addition to potentially immunologically relevant (neo-)antigens, tens of thousands of endogenous peptides naturally presented on HLA-I molecules are identified in such HLA peptidomics studies, providing a unique opportunity to collect very large numbers of HLA-I ligands that can be used to better understand the binding properties of HLA-I molecules. The challenge in studying HLA-I motifs based on such pooled peptidomics data from unmodified cell lines or tissue samples is to determine the allele on which each peptide was displayed. The most widely used approach is to predict binding affinity of each peptide to each allele present in a sample \[[@pcbi.1005725.ref021]\]. Recent studies by ourselves and others have shown that HLA-I motifs can be identified in HLA peptidomics datasets in an unsupervised way by grouping peptides based on their sequence similarity \[[@pcbi.1005725.ref017],[@pcbi.1005725.ref022]--[@pcbi.1005725.ref025]\]. However, this strategy still relies on previous information about HLA-I binding specificity when associating predicted motifs with HLA-I alleles and is therefore restricted to alleles whose motifs have been already characterized.

Here, we describe a computational framework for direct identification and annotation of dozens of HLA-I motifs without any *a priori* information about HLA-I binding specificity by taking advantage of co-occurrence of HLA-I alleles across both newly generated and publicly available HLA peptidomics datasets. Our approach recapitulates and refines motifs for many common alleles and uncovers new motifs for eight alleles for which, until this study, no ligand had been documented. Importantly, this approach is highly scalable and will enable continuous refinement of motifs for known alleles and determination of novel motifs for uncharacterized alleles as more HLA peptidomics data will be acquired in the future. Training HLA-I ligand predictors based on the refined motifs significantly improves neo-antigen predictions in tumor samples with experimentally determined neo-antigens. Our large collection of HLA-I ligands further allowed us to unravel some of the molecular determinants of HLA-I binding motifs and revealed allosteric modulation of HLA-I binding specificity. To elucidate the underlying molecular mechanisms, we show how a single point mutation (W97R) in HLA-B14:02 outside of the B pocket significantly changes the amino acid preferences at P2 in the ligands.

Results {#sec002}
=======

Fully unsupervised identification of HLA-I binding motifs {#sec003}
---------------------------------------------------------

To study the binding properties of HLA-I alleles without relying on *a priori* assumption on their binding specificity and investigate whether this unbiased approach could improve neo-antigen predictions from exome sequencing data, we reasoned that HLA-I binding motifs might be identified across samples with in-depth and accurate HLA peptidomics data by taking advantage of co-occurrence of HLA-I alleles. To this end, we measured the HLA peptidome eluted from six B cell lines, two *in vitro* expanded tumor-infiltrating lymphocytes (TILs) samples and two leukapheresis samples (peripheral blood mononuclear cells) selected based on their high diversity of HLA-I alleles (see [Methods](#sec011){ref-type="sec"} and [S1 Dataset](#pcbi.1005725.s002){ref-type="supplementary-material"}). By applying a stringent false discovery rate for peptides identification of 1%, we accurately identified 47,023 unique peptides displayed on 32 HLA-I molecules. To expand the coverage of HLA-I alleles, we further collected 40 publicly available high-quality HLA peptidomics datasets \[[@pcbi.1005725.ref017],[@pcbi.1005725.ref018],[@pcbi.1005725.ref022],[@pcbi.1005725.ref023],[@pcbi.1005725.ref026]--[@pcbi.1005725.ref028]\] (see [Methods](#sec011){ref-type="sec"} and [S2 Dataset](#pcbi.1005725.s003){ref-type="supplementary-material"}). Our final data consists of a total of 50 HLA peptidomics datasets covering 66 different HLA-I alleles (18 HLA-A, 32 HLA-B and 16 HLA-C alleles, see Table A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). The number of unique HLA-I ligand interactions across all samples reaches 252,165 for a total of 119,035 unique peptides (9- to 14-mers), which makes it, to our knowledge, the largest currently available collection of HLA peptidomics datasets both in terms of number of peptides and diversity of HLA-I molecules. Binding motifs in each HLA peptidomics dataset were identified for 9- and 10-mers (see Fig A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) using a motif discovery algorithm initially developed for multiple specificity analysis \[[@pcbi.1005725.ref029],[@pcbi.1005725.ref030]\] and recently applied to the analysis of a small dataset of seven HLA peptidomics studies \[[@pcbi.1005725.ref024]\]. Importantly, this method does not rely on HLA-I peptide interaction predictions (see [Methods](#sec011){ref-type="sec"}).

To assign each motif to its allele even in the absence of *a priori* information about the alleles' binding specificity, we developed a novel computational strategy illustrated in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}. In this example, one allele (HLA-A24:02) was shared between all three samples. Remarkably, exactly one identical motif was shared between the three samples. As such, one can predict that this motif corresponds to the shared allele. Similarly, two alleles (HLA-A01:01 and HLA-C06:02) were shared between exactly two samples and here again two motifs were shared among the corresponding samples, and could therefore be annotated to their corresponding alleles. Moreover, if one sample shares all but one allele with another sample, it can be inferred that the motif that is not shared corresponds to the unshared allele (see example in Fig B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), even if some of the shared motifs have not been annotated yet. Finally, if all but one motif had been annotated in a sample to all but one allele, one can infer that the remaining motif corresponds to the remaining allele. These three ideas can then be recursively applied to identify HLA-I motifs across our large collection HLA peptidomics datasets (see [Methods](#sec011){ref-type="sec"}). Of note, motifs identified in distinct samples that have some alleles in common show very high similarity ([Fig 1](#pcbi.1005725.g001){ref-type="fig"} and Fig B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) and our new approach builds upon this remarkable inherent reproducibility of in-depth and accurate HLA peptidomics data.

![General pipeline for HLA-I motif identification and annotation, and training of predictors.\
High accuracy HLA peptidomics data were first generated for 10 samples and collected from publicly available data for 40 other samples. In each sample motifs were identified using on our recent mixture model algorithm \[[@pcbi.1005725.ref024]\]. Motifs were then annotated to their respective allele based on co-occurrence of alleles across samples (e.g., first HLA-A24:02, then HLA-A01:01 and HLA-C06:02, see also Fig B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} for another example). Finally all peptides assigned to each motif were pooled together to train our new HLA-I ligand predictor for each HLA-I allele (MixMHCpred v1.0).](pcbi.1005725.g001){#pcbi.1005725.g001}

We applied our algorithm to the 50 HLA peptidomics datasets considered in this study. In total, motifs could be found for 44 different alleles without relying on any *a priori* assumption of HLA-I binding specificity ([Fig 2A](#pcbi.1005725.g002){ref-type="fig"}). These include seven alleles (HLA-B13:02, HLA-B14:01, HLA-B15:11, HLA-B15:18, HLA-B18:03, HLA-B39:24 and HLA-C07:04) that did not have known ligands in IEDB, and 5 additional ones (HLA-B38:01, HLA-B39:06, HLA-B41:01, HLA-B56:01, HLA-C07:01) that had less than 50 known ligands. To validate our predictions, we compared the motifs predicted by our fully unsupervised method with known motifs derived from IEDB \[[@pcbi.1005725.ref004]\], when available. Despite some differences (e.g. HLA-A25:01 motif at P9) affecting especially alleles with low number of ligands in IEDB (Fig C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), we observed an overall high similarity confirming the reliability of our predicted motifs ([Fig 2A](#pcbi.1005725.g002){ref-type="fig"}). However, it is important to realize that even small differences in the motifs can have important effects on the performance of predictors that are trained on such data when ranking very large lists of potential epitopes. When comparing with data recently obtained by HLA peptidomics analysis of mono-allelic cell lines \[[@pcbi.1005725.ref031]\], a very high similarity was also observed ([Fig 2B](#pcbi.1005725.g002){ref-type="fig"}, stars in Fig C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), which further validates our computational approach for HLA-I motif identification and annotation from in-depth pooled HLA peptidomics data.

![Comparison between motifs predicted by our algorithm and known motifs.\
**A**: Comparison with IEDB motifs for 44 HLA-I binding motifs identified with the fully unsupervised approach. Alleles without previously documented ligands are highlighted in red. For HLA-B56:01, the three known ligands are shown. **B**: Comparison with motifs obtained from mono-allelic cell lines \[[@pcbi.1005725.ref031]\]. **C**: Motif identified with the semi-supervised approach.](pcbi.1005725.g002){#pcbi.1005725.g002}

As expected from many previous studies, alleles with the same two first digits code showed high similarity in their binding specificity, apart from HLA-B15 alleles which are known to be more diverse \[[@pcbi.1005725.ref032]\]. This includes many of the new motifs (e.g., HLA-B14:01 vs HLA-B14:02; HLA-B18:03 vs HLA-B18:01; HLA-B39:24 vs HLA-B39:06), which provides further evidences of the accuracy of our predictions for these uncharacterized alleles.

Semi-supervised approach {#sec004}
------------------------

For the most frequent HLA-I alleles, including several shown in [Fig 2A](#pcbi.1005725.g002){ref-type="fig"}, a good description of their binding motifs can be already obtained from existing databases \[[@pcbi.1005725.ref004]\]. To further expand our collection of HLA-I binding motifs, we used similarity to the binding motifs derived from IEDB ligands to annotate motifs that could not be assigned to their corresponding allele by the fully unsupervised algorithm, following the approach previously introduced by ourselves in ref \[[@pcbi.1005725.ref024]\] (see [Methods](#sec011){ref-type="sec"}). This enabled us to determine the binding motifs of 8 additional alleles ([Fig 2C](#pcbi.1005725.g002){ref-type="fig"}). Of note, the new motif of HLA-A02:20 was predicted by observing that it was the only motif not annotated in one sample (RA957) and could only be annotated to this allele based on the motifs identified in other samples for all the other alleles (see Fig A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). The final list of motifs for the 52 alleles and detailed comparison with IEDB derived data, when available, is shown in Fig D in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}. Importantly, for the majority of alleles considered in this study, the motifs are supported by significantly more ligands than what is available in existing databases (Fig E in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), and in total our approach enabled us to collect 88'051 unique 9-mer peptide HLA-I interactions for all alleles annotated in this work, compared to the 57'651 interactions available in IEDB for the same set of alleles. 14 out of a total of 195 motifs (corresponding to 5'703 9-mer peptide-HLA interactions) could not be annotated by our approach (see Fig A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

To investigate how our approach depends on the number of samples in which a motif is found, we show in Fig F in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} the distance between our predicted motifs and those derived from mono-allelic cell lines (Fig F(a) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) or those pooled from all samples (Fig F(b) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) as a function of the number of samples (i.e. sub-sampling). As expected, higher similarity could be observed by integrating several samples, justifying our idea of collecting as much data as possible from different HLA peptidomics datasets to refine our motifs. But overall, all distances are very small (D^2^ \< 0.03), highlighting the excellent reproducibility of the motifs deconvoluted from HLA peptidomics datasets.

To explore the statistical significance of the motifs associated to the same alleles, we followed the approach of ref. \[[@pcbi.1005725.ref033]\] and compared the similarity (both Euclidean distance and BLiC score) between each pair of motifs (*m*~*i*~, *m*~*j*~) annotated to the same allele *h* (*i = 1*, *...N*~*h*~, *j = 1...N*~*h*~, *i≠j* with *N*~*h*~ the number of motif annotated to allele *h*) to the distribution of similarity values between motif *m*~*i*~ and all known HLA-I motifs \[[@pcbi.1005725.ref033]\] (see [Methods](#sec011){ref-type="sec"}). Fig G in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} shows that more than 99% of the pairs of motifs associated to the same alleles have a statistically significant similarity (P\<0.05), confirming the few examples shown in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}. Exceptions consist mainly of motifs annotated to HLA-C alleles, which are more degenerate and therefore more difficult to deconvolute \[[@pcbi.1005725.ref024]\]. We therefore recognize that our motifs are likely less accurate for HLA-C alleles, but emphasize that these alleles are also poorly described in existing databases or literature.

We further explored the effect of the threshold T = 0.078 on Euclidean distance manually defined in this work (see [Methods](#sec011){ref-type="sec"}). As expected lower values of T still results in highly similar motifs annotated to the same alleles, but in fewer alleles to which motifs can be annotated (Fig H in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). Reversely, larger values tend to increase the number of alleles with annotated motifs, but at some point (T\>0.09) more distinct motifs (P\>0.05, based on Euclidean distance) become associated to the same alleles (Fig H in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

The full pipeline was also applied on 10-mers identified by MS across the 50 HLA peptidomics studies and revealed six new motifs for poorly characterized alleles in IEDB (Fig I in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

Investigating inherent technical biases in HLA peptidomics studies {#sec005}
------------------------------------------------------------------

Different technical biases may affect MS data, which could undermine their use for training HLA-I ligand predictors. To investigate this potential issue, we computed amino acid frequencies at non-anchor positions (P4 to P7) in our HLA peptidomics data, excluding alleles displaying anchor residues at these positions (see [Methods](#sec011){ref-type="sec"} and Table B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). The reason for focusing on middle positions is that they display low specificity (especially in 9-mers, see discussion in \[[@pcbi.1005725.ref024],[@pcbi.1005725.ref034],[@pcbi.1005725.ref035]\] for longer peptides) and therefore could provide a global view of potential MS biases on amino acid frequencies that is not affected by the constraints of binding to HLA-I molecules.

As expected, we observed a good correlation between amino acid frequencies at non-anchor positions in our HLA peptidomics data and in the human proteome (r = 0.85) ([Fig 3](#pcbi.1005725.g003){ref-type="fig"} and Fig J in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). The most important difference that could strongly affect predictors trained on such data was found for cysteine, which is prone to post-translational modifications that are typically not included in database searches and was observed at very low frequency in the HLA peptidomics data (the same observation was recently made in mono-allelic cell lines \[[@pcbi.1005725.ref031]\]). Moreover, IEDB data clearly indicate that cysteine can be found at non-anchor positions, including for immunogenic epitopes, and therefore the low frequency observed in MS data very likely corresponds to a technical bias. Other amino acids were less under- or over-represented and the differences observed with the human proteome may also reflect some residual specificity at non-anchor positions. Moreover, no clear pattern emerged from these data with respect to amino acid biophysical properties (e.g., charge, hydrophobicity, size). Overall, our results suggest that HLA peptidomics data do not show strong technical biases, apart from under-representation of cysteine (see next section for a proposed method on how to compensate this bias), and therefore could provide ideal data for training HLA-I peptide interaction predictors, especially for ligands coming from human cells like neo-antigens.

![Correlation between amino acids frequencies at positions P4 to P7 in our HLA peptidomics data and in the human proteome.](pcbi.1005725.g003){#pcbi.1005725.g003}

Training HLA-I ligand predictors {#sec006}
--------------------------------

To test whether our unique dataset of naturally presented peptides could help predicting HLA-I ligands, including neo-antigens in tumors based on exome sequencing data, we trained a predictor of HLA-I ligands (referred to as MixMHCpred). As MS only includes positive examples and HLA-I ligands in general do not show strong amino acid correlations between different positions (see discussion in \[[@pcbi.1005725.ref024]\] for some exceptions), we built Position Weight Matrices (PWMs) for each of the 52 alleles. These PWMs were built by pooling together all peptides assigned to each allele across all our HLA peptidomics datasets (see [Methods](#sec011){ref-type="sec"} and [Fig 1](#pcbi.1005725.g001){ref-type="fig"}). We further included MS data from mono-allelic cell lines for 6 rare alleles that were not present in our dataset, resulting in a total of 58 alleles available in our predictor. To correct for the low detection of cysteine observed in HLA peptidomics data we further renormalized our predictions by amino acid frequencies at non-anchor positions (see [Methods](#sec011){ref-type="sec"} and Table B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

As a first validation, we attempted to re-predict naturally presented peptides experimentally identified in ten mono-allelic cell lines whose alleles overlapped with our dataset \[[@pcbi.1005725.ref031]\]. For this analysis, we did not include data from these mono-allelic cell lines in our training set. To assess our ability to predict naturally presented peptides, we added 99-fold excess of decoy peptides randomly selected from the human proteome to each mono-allelic cell line dataset and measured the fraction of Positives among the top 1% Predictions (PP1%, i.e., True Positive Rate among the top 1%), which in the case of 99-fold excess of decoy is equivalent to both the Precision and the Recall, since the number of predictions (top 1%) is equal to the number of actual positives (1%). For all but one allele, our algorithm showed higher or equal predictive power compared to standard HLA-I ligand predictors \[[@pcbi.1005725.ref008],[@pcbi.1005725.ref012],[@pcbi.1005725.ref036]\] ([Fig 4A](#pcbi.1005725.g004){ref-type="fig"}). We further measured the average Area Under the Curve (AUC) for these alleles and obtained quite similar values (0.978 for MixMHCpred, 0.976 for NetMHC, 0.979 for NetMHCpan and 0.977 for NetMHCstabpan). However, we emphasize that most random peptides used as negatives are quite distinct from the positives, which can explain the very high AUC values and we suggest that precision values for top 1% of the predictions shown in [Fig 4A](#pcbi.1005725.g004){ref-type="fig"} are more representative of the actual performance of the algorithms.

![Comparison between our predictor (MixMHCpred1.0) and existing tools.\
**A**: Fraction of the true positives among the top 1% predictions (PP1%) for the naturally presented HLA-I ligand identified in mono-allelic cell lines, with 99-fold excess of decoy peptides. Of note, PP1% is equivalent to the both Precision and Recall, since the number of actual positives is the same as the number of predicted positives. **B-C**: Graphical representation of results in [Table 1](#pcbi.1005725.t001){ref-type="table"} and Table C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}. Panel B shows the AUC values and panel C the fraction of neo-antigens predicted in the top 1% of predictions (which typically corresponds to what is experimentally tested for immunogenicity). **D-E**: Predictions of Cancer Testis Antigens from the CTDatabase. Panel D shows AUC values and panel E shows PP1%. Truncated y-axes are explicitly indicated.](pcbi.1005725.g004){#pcbi.1005725.g004}

Predictions of neo-antigens and cancer testis antigens {#sec007}
------------------------------------------------------

We then collected currently available datasets that included direct identification of neo-antigens displayed on cancer cells as well as exome sequencing data (Mel5, Mel8, Mel15 from \[[@pcbi.1005725.ref017]\] and 12T from \[[@pcbi.1005725.ref020]\]) for a total of ten 9- and 10-mers mutated peptides experimentally found to be presented on cancer cells (see [Table 1](#pcbi.1005725.t001){ref-type="table"}). This dataset has the unique advantage of not being restricted to peptides selected based on *in silico* predictions, and is therefore an ideal testing set for benchmarking our predictor. Moreover, as these studies are quite recent, the neo-antigens used here as testing set are not part of the training set of any existing algorithm. In particular, they are not part of the large training set used in this study since we only included wild-type human peptides in our pipeline. We then retrieved all possible 9- and 10-mer peptides that encompassed each missense mutation ([S3 Dataset](#pcbi.1005725.s004){ref-type="supplementary-material"}) and ranked separately for each patient these potential neo-antigens based on the score of our predictor (see [Methods](#sec011){ref-type="sec"} and [Table 1](#pcbi.1005725.t001){ref-type="table"}). Remarkably, six of the ten neo-antigens fell among the top 25 predicted peptides, suggesting that by testing as few as 25 mutated peptides per sample, we could identify more than half of the neo-antigens identified by MS ([Table 1](#pcbi.1005725.t001){ref-type="table"}). Considering that the total number of potential neo-antigens (i.e. 9- and 10-mers containing a missense mutation) can be as large as 25,000 for tumors with high mutational load, our predictor trained on naturally presented human HLA-I ligands clearly enabled us to significantly reduce the number of peptides that would need to be experimentally tested to identify neo-antigens from exome sequencing data. We further added two datasets of neo-antigens identified in lung cancer patients (L011 and L013) \[[@pcbi.1005725.ref037]\], although only peptides pre-selected based on binding affinities predicted with existing tools \[[@pcbi.1005725.ref012]\] were tested in this study. Here again, our predictor ranked one neo-antigen in the top 25 predicted peptides in both samples (Table C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). When comparing with standard tools that are widely used to narrow-down the list of potential neo-antigens predicted from exome sequencing data \[[@pcbi.1005725.ref008],[@pcbi.1005725.ref012],[@pcbi.1005725.ref036]\], our method trained on HLA peptidomics data showed clear improvement ([Table 1](#pcbi.1005725.t001){ref-type="table"}) with a mean AUC value of 0.979, compared to 0.932 for NetMHC \[[@pcbi.1005725.ref008]\], 0.942 for NetMHCpan \[[@pcbi.1005725.ref012]\] and 0.945 for NetMHCstabpan \[[@pcbi.1005725.ref036]\] ([Fig 4B](#pcbi.1005725.g004){ref-type="fig"}) and increased number of neo-antigens in the top 1% of the predictions (i.e., typically what is experimentally tested for immunogenicity) across all six samples ([Fig 4C](#pcbi.1005725.g004){ref-type="fig"}). This is especially clear for the 12T sample, where the single neo-antigen was very well predicted by our model and poorly predicted by existing tools (\>6'000nM with HLA-B51:01, see also [Table 1](#pcbi.1005725.t001){ref-type="table"} and \[[@pcbi.1005725.ref020]\]). We still note that, due to the low number of neo-antigens publicly available together with exome sequencing data, performance metrics in [Fig 4B and 4C](#pcbi.1005725.g004){ref-type="fig"} can be sensitive to one neo-antigen being better or less well predicted and we stress that the values shown in [Fig 4B and 4C](#pcbi.1005725.g004){ref-type="fig"} are simply a graphical way of looking at data shown in [Table 1](#pcbi.1005725.t001){ref-type="table"} and Table C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}. Importantly, even if we did not include in the training of our predictor MS data (i.e. wild-type peptides) from the samples in which the neo-antigens were identified, neo-antigens were still more accurately predicted compared to other tools (see Fig K in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). This demonstrates that our approach for neo-antigen predictions from the list of somatic mutations identified by exome sequencing of tumors does not require HLA peptidomics data from the same sample where neo-antigens had been identified. Nevertheless, both our predictor and standard prediction tools failed to identify some neo-antigens (e.g., KLILWRGLK from NCAPG2 P333L mutation, see [Table 1](#pcbi.1005725.t001){ref-type="table"}). This suggests that, when enough tumor material is available for HLA peptidomics analyses, direct identification of neo-antigens with MS should still be performed to optimally enrich in true positives the list of ligands to be experimentally tested for immunogenicity \[[@pcbi.1005725.ref016],[@pcbi.1005725.ref019]\].

10.1371/journal.pcbi.1005725.t001

###### Ranking of the neo-antigens identified in four melanoma samples \[[@pcbi.1005725.ref017],[@pcbi.1005725.ref020]\].

Column 2 shows the mutated neo-antigens (the mutated residue is highlighted in bold). Column 5 shows the ranking based on our predictions (i.e. number of peptide to be tested to find this neo-antigen). Columns 6 to 8 show the ranking based on NetMHC \[[@pcbi.1005725.ref008]\], NetMHCpan \[[@pcbi.1005725.ref012]\] and NetMHCstabpan \[[@pcbi.1005725.ref036]\], respectively. The last column shows the total number of neo-antigen candidates (i.e., all possible 9- and 10-mers encompassing all missense mutations).

![](pcbi.1005725.t001){#pcbi.1005725.t001g}

  Sample   Sequence       Protein   Mutation   Rank      Net-MHC    Net-MHCpan   Net-MHC-stabpan   \# Candi-dates
  -------- -------------- --------- ---------- --------- ---------- ------------ ----------------- ----------------
  Mel8     `SPGPVKLEL`    NOP16     P169L      **2**     7          7            14                1340
  Mel5     `YIDERFERY`    SEPT2     Q125R      **3**     13         37           149               25807
  Mel5     `ETSKQVTRW`    GABPA     E161K      **13**    2088       1755         581               25807
  Mel15    `GRIAFFLKY`    SYTL4     S363F      **3**     139        410          481               24766
  Mel15    `LPIQYEPVL`    SEC23A    P52L       **7**     1717       672          36                24766
  Mel15    `KLKLPIIMK`    AKAP6     M1482I     **21**    198        100          44                24766
  Mel15    `GRTGAGKSFL`   ABCC2     S1342F     **243**   1115       2085         3207              24766
  Mel15    `KLILWRGLK`    NCAPG2    P333L      527       301        **184**      199               24766
  Mel15    `ASWVVPIDIK`   MAP3K9    E689K      3978      **1654**   1351         3079              24766
  12T      `DANSFLQSV`    MED15     P747S      **38**    4206       4176         3181              15750

The number of studies reporting both neo-antigens and exome sequencing results is still limited. To benchmark our algorithm with larger datasets of immunologically relevant tumor antigens, we tested our ability to predict epitopes from cancer testis antigens. We retrieved all epitopes listed in the CT database \[[@pcbi.1005725.ref038]\] (see [Methods](#sec011){ref-type="sec"} and Table D in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). We then assessed how our predictor could prioritize these epitopes from all possible peptides encoded by these cancer testis antigens. Although we cannot exclude that some of these epitopes had been selected for experimental testing after prediction by older versions of HLA-I ligand predictors, we still observed improvement using our predictor trained only on naturally presented HLA-I ligands, both in terms of AUC and fraction of true positives that fall in the top 1% of the predictions ([Fig 4D and 4E](#pcbi.1005725.g004){ref-type="fig"}). This indicates that improvement in prediction accuracy is not restricted to elution data (see similar results in \[[@pcbi.1005725.ref024]\]).

MS data can contain false positives for many different reasons, such as co-eluting peptide contaminations or errors in the computational identification of peptides from the spectra. Therefore, despite the high quality of HLA peptidomics datasets generated in this study (\<1% FDR), we do expect our data to contain some noise. To test the robustness towards contaminations of our motif discovery and annotation pipeline, and our HLA-I ligand predictor, we incorporated 5% of random peptides from the human proteome into all HLA peptidomics datasets considered in this work and rerun the whole motif annotation pipeline and training of the predictor. Remarkably, the accuracy of the predictions was only very modestly affected by this noise and predictions were still better than with other existing tools (Fig L in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). To explore the effect of wrong peptide identification, we reprocessed with MaxQuant \[[@pcbi.1005725.ref039]\] the three MS samples shown in [Fig 1](#pcbi.1005725.g001){ref-type="fig"} and chose the second best hit for 1% of the peptides. Overall the motifs predicted by our approach remained almost unchanged (Fig M in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). This suggests that our pipeline is robust and indicates that the wealth of unbiased and accurate data provided by MS can compensate the inherent contaminations, when using these data for training HLA-I ligand predictors.

An important step in our predictor is the renormalization by amino acid frequencies observed at non-anchor positions, which was designed to correct for biases in MS data. As expected, doing this renormalization step with amino acid frequencies observed in the human proteome (or no renormalization at all) results in very low frequency of cysteine-containing peptides among the top predicted ligands. As such, it improves the predictions of MS data (see especially Fig N(a) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), but decreases the performance in other datasets (e.g., Fig N(b-c) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} for L011 and L013). These results highlight the importance of carefully considering MS biases when including such data to train predictors in order to avoid over-fitting elution data. We anticipate that additional work may further improve this step, such as inclusion of cysteine modifications in spectral searches \[[@pcbi.1005725.ref031]\] or better estimations of the expected baseline amino acid frequencies in HLA peptidomics datasets.

Analysis of the newly identified motifs {#sec008}
---------------------------------------

One of our novel HLA-I motifs describes the binding specificity of HLA-A02:20 ([Fig 2C](#pcbi.1005725.g002){ref-type="fig"}). HLA-A02 binding motifs have been widely studied. However, HLA-A02:20 motif differs from standard HLA-A02 motifs at P1, with a clear preference for charged residues ([Fig 5A](#pcbi.1005725.g005){ref-type="fig"}). Interestingly, HLA-A02:20 is among the very few (\<2%) HLA-A02 alleles that do not have a conserved lysine pointing towards P1 at position 66 (residue numbering follows 2BNQ X-ray structure hereafter). Instead an asparagine is found there ([Fig 5A](#pcbi.1005725.g005){ref-type="fig"}), and this residue is the only difference with the sequence of the very common A02:01 allele. To explore how the absence of lysine at position 66 could explain the observed difference in binding specificity, we collected all HLA-I alleles showing preference for charged amino acids at P1 (see Fig O in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). All of them had either asparagine or isoleucine at position 66. We then explored available crystal structures of HLA-I peptide complexes with charged residues at P1. HLA-B57:03 was crystalized with such a ligand (KAFSPEVI) \[[@pcbi.1005725.ref040]\]. Superposing the crystal structure of this complex with the structure of HLA-A02:01 provides a possible mechanism for understanding the change in binding specificity at P1. In HLA-A02:01, lysine at position 66 interacts with the hydroxyl group of serine at P1 ([Fig 5A](#pcbi.1005725.g005){ref-type="fig"}, green sidechains). Such a conformation would not be compatible with a longer residue. Reversely, when asparagine was found at position 66, it did not point towards P1 ([Fig 5A](#pcbi.1005725.g005){ref-type="fig"}, pink sidechains), thereby freeing space for larger sidechains like lysine or arginine at P1. Overall, our analysis indicates that the presence of asparagine at residue 66 may be responsible for the change in binding specificity between HLA-A02:01 and HLA-A02:20. More generally, our results suggest that lysine at residue 66 in HLA-I alleles strongly disfavours charged residues at P1.

![Analysis of newly identified HLA-I motifs.\
**A**: Structural view of two different HLA-I alleles with N90 as in HLA-A02:20 (PDB: 2BVQ \[[@pcbi.1005725.ref040]\], pink sidechains) or K90 as in HLA-A02:01 (PDB: 2BNR \[[@pcbi.1005725.ref041]\], green sidechains). For clarity, the α~1~ helix has been truncated. **B**: B pocket residues' conservation across HLA-I alleles displaying preference for histidine at P2. The last line shows the sequence of HLA-B14:02, which does not show histidine preference at P2 (see motif in **C**), but has the same B pocket as HLA-B15:18. The last column shows amino acids at position 97, which is not part of the B pocket. **C**: Structural view of HLA-B14:02 in complex with a peptide with arginine at P2 (PDB: 3BVN \[[@pcbi.1005725.ref042]\]). Residues not conserved between HLA-B15:18 and HLA-B14:02 are displayed in orange. None of them are making direct contact with the arginine residue at P2. **D**: Stability values (half-lives) obtained for peptides with H or R at P2 for both HLA-B14:02 wt and W97R mutant. NB stands for no binding. Dashed lines indicate lower bounds for half-lives values. Residue numbering follows the one used in most X-ray structures in the PDB.](pcbi.1005725.g005){#pcbi.1005725.g005}

The new motif identified for HLA-B15:18 ([Fig 2A](#pcbi.1005725.g002){ref-type="fig"}) displayed strong preference for histidine at P2, which is not often observed in HLA-I ligands. To gain insights into the mechanisms underlying this less common binding motif, we surveyed all alleles that show preference for histidine at P2 (Fig P(a) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). Sequence and structure analysis showed that all of them have a conserved P2 binding site, commonly referred to as the B pocket (see [Fig 5B](#pcbi.1005725.g005){ref-type="fig"}). However, several HLA-B14 alleles have exactly the same B pocket but show specificity for arginine at P2 (Fig P(b) in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). Among them, HLA-B14:02 had the highest sequence similarity to HLA-B15:18, with only 8 different residues in the peptide binding domain, none of them making any contact with arginine at P2 in the crystal structure of HLA-B14:02 (orange residues in [Fig 5C](#pcbi.1005725.g005){ref-type="fig"}). This suggests that the difference in binding specificity at P2 between HLA-B14:02 and HLA-B15:18 is likely explained by allosteric mechanisms. Of particular interest is residue 97 (W in HLA-B14:02 and R in HLA-B15:18), which is in the HLA-I binding site and contacts the peptide (mainly P3 to P6, [Fig 5C](#pcbi.1005725.g005){ref-type="fig"}) but is more than 7Å away from the arginine sidechain at P2. This residue is part of a network of aligned aromatic residues (Y9, W97 and F116) in HLA-B14:02 ([Fig 5C](#pcbi.1005725.g005){ref-type="fig"}) compatible with pi-pi interactions. Interestingly, X-ray structures with Arg at position 97 (e.g., 4O2C) show a flip in the orientation of Y9 sidechain, which reduces the size of the B pocket. We therefore hypothesized that mutating residue 97 into arginine in HLA-B14:02 may indirectly modify the binding specificity at P2 and explain the preference for histidine observed in the HLA-B15:18 motif.

Molecular mechanism underlying distant modulation of HLA-I binding specificity at P2 {#sec009}
------------------------------------------------------------------------------------

To test our hypothesis, we generated a construct for HLA-B14:02 wild-type (wt) and W97R mutant. We tested several ligands of HLA-B15:18 identified in our HLA peptidomics data with histidine at P2, which were predicted to show enhanced binding to HLA-B14:02 W97R. As expected, a strong decrease in binding stability was observed between HLA-B14:02 W97R and HLA-B14:02 wt ([Fig 5D](#pcbi.1005725.g005){ref-type="fig"}). Reversely, when testing the same peptides with arginine at P2, a significant increase in stability was observed between HLA-B14:02 W97R and HLA-B14:02 wt ([Fig 5D](#pcbi.1005725.g005){ref-type="fig"}). For instance, binding of the peptide AHTKPRPAL was fully abolished in HLA-B14:02 wt, but was rescued when changing histidine to arginine at P2. Although other residues may also play a role in the binding specificity differences between HLA-B14:02 and HLA-B15:18, all of them are further away from P2. Overall, our results show that HLA-I binding specificity at P2 can be modulated by amino acids outside of the B pocket, and that residue 97 can act as a switch of the binding specificity at P2. These binding experiments further confirm the motifs predicted for HLA-B14:01 and HLA-B15:18 alleles.

Discussion {#sec010}
==========

Despite decades of work to characterize the binding motifs of the most common HLA-I alleles, unbiased peptide screening approaches have not been commonly used in the past. This is mainly because both the N- and the C-terminus of the peptides are engaged in binding to HLA-I molecules, thereby preventing the use of high-throughput techniques for peptide screening like phage display. To address this issue, we developed a novel algorithm to rapidly identify and annotate HLA-I binding motifs in a fully unsupervised way using in-depth and accurate HLA peptidomics data from unmodified cell lines and tissue samples. This enabled us to refine models of binding specificity for many alleles with few ligands in existing databases and characterize the binding properties of eight HLA-I alleles that had no known ligands until this study. Our approach is conceptually similar to existing approaches to deconvolute peptide epitopes by identifying shared peptides between different pools showing T cell reactivity in ELISpot experiments, but had never been applied to motif annotation across HLA peptidomics datasets.

Remarkably, our predicted motifs displayed high similarity with known motifs for common alleles, including motifs derived from HLA peptidomics analyses of mono-allelic cell lines \[[@pcbi.1005725.ref031]\] ([Fig 2](#pcbi.1005725.g002){ref-type="fig"}), and the MS-induced technical bias (mainly low detection of cysteine) could be compensated by renormalization with expected amino acid frequencies. This suggests that HLA peptidomics data are optimal to train HLA-I ligand interaction predictors, as confirmed by our ability to accurately predict from exome sequencing data several neo-antigens identified in tumor samples. These observations are in line with recent results obtained with predictors trained on HLA peptidomics data from mono-allelic cell lines for 16 human class I alleles \[[@pcbi.1005725.ref031]\] and mouse class II alleles \[[@pcbi.1005725.ref043]\]. Moreover, similar results seem to be observed when including MS data in the training set of NetMHCpan tools \[[@pcbi.1005725.ref044]\]. Although mass spectrometry may miss a fraction of the actually presented and immunogenic neo-antigens, those detected by MS are likely presented at high level on cancer cells. Therefore, accurately predicting such dominant neo-antigens is promising to prioritize targets for cancer immunotherapy.

Importantly, the improvement in prediction accuracy we report here comes primarily from refinement of known HLA-I motifs, since the less frequent alleles for which we uncovered new motifs were in general not part of our testing sets. For instance, differences are observed at P9 between the motif of HLA-A25:01 obtained from HLA peptidomics data (preference for F/W/Y/L) and from IEDB ligands (preference for Y/L/M/F) ([Fig 2A](#pcbi.1005725.g002){ref-type="fig"}). This likely explains why the neo-antigen `ETSKQVTRW` was poorly predicted by standard tools \[[@pcbi.1005725.ref008],[@pcbi.1005725.ref012]\] (predicted IC~50~ \> 3,000nM). Similar observations apply for the neo-antigen `DANSFLQSV` found in \[[@pcbi.1005725.ref020]\] (predicted IC~50~ \> 6,000nM with HLA-B51:01). Although these differences may look relatively small on the logos ([Fig 2A](#pcbi.1005725.g002){ref-type="fig"}), they play an important role when ranking tens of thousands of potential epitopes with HLA-I ligand predictors. Moreover, as our predictor is only trained on naturally presented ligands, it may also capture some features of antigen presentation of endogenous peptides beyond the binding to HLA-I molecules. Along this line, it is interesting to note that a smaller improvement in prediction accuracy had been observed when attempting to predict ligands from the SYFPEITHI database \[[@pcbi.1005725.ref045]\] (including a large fraction of viral peptides) with HLA peptidomics data \[[@pcbi.1005725.ref024]\]. Although the dataset used in this previous study was significantly smaller, this observation suggests that HLA peptidomics data may be especially well suited for training predictors of human endogenous or mutated HLA-I ligands. Overall, our work highlights the importance of carefully determining HLA-I motifs, including for alleles that already have some known ligands, based on unsupervised analysis of naturally presented human HLA-I ligands for neo-antigen discovery.

In this work, we did not attempt to optimize the prediction algorithm itself, but rather focused on optimizing the training data and carefully correcting for MS biases, which in our view is more important for improving predictions of HLA-I ligands, since HLA-I ligands do not display strong correlations among the different residue positions. Nevertheless, we cannot exclude that using neural networks or other machine learning tools may further improve the predictions, and we anticipate that our large collection and assignment of unbiased HLA-I ligands may help exploring new amino acid correlation patterns among HLA-I ligands (see example in \[[@pcbi.1005725.ref024]\]).

Currently our predictor is limited to 9- and 10-mers, which is the most common length of HLA-I ligands and accounts for more than 80% of the HLA peptidome \[[@pcbi.1005725.ref017]\]. Although motif identification may work in some cases for 11-mers \[[@pcbi.1005725.ref024]\], the automated motif deconvolution and annotation becomes less accurate, especially for samples with less than 10'000 peptides identified by MS. Therefore, rather than including sub-optimal motifs in our predictor, we focused in this work on 9- and 10-mers. We anticipate that manual curation of HLA-I motifs in pooled HLA peptidomics datasets or the use of mono-allelic cell lines \[[@pcbi.1005725.ref031]\] may be more appropriate for training predictors for longer peptides. Importantly, not including 11-mers has no influence on the predictions for 9- and 10-mers, since peptides of different length are treated separately in the current framework (see ref. \[[@pcbi.1005725.ref008]\] for possible algorithmic extensions to include peptides of different length in the training set of HLA-I ligand predictors).

Our work enabled us to identify motifs for uncharacterized alleles and is to date the predictor entirely trained on naturally presented peptides with the largest allelic coverage, including all frequent HLA-I alleles in the Caucasian population. However, the number of HLA-I alleles for which predictions are available (58 in total) is still smaller than what other tools can do (especially tools like NetMHCpan \[[@pcbi.1005725.ref012]\] that can make predictions for any allele). Despite this limitation, we emphasize that our work provides the first scalable framework to integrate HLA peptidomics datasets that will be or are being generated for neo-antigen discovery in cancer immunotherapy and therefore will enable increasing the allele coverage as new studies are published. Moreover, our results suggest that improving existing models describing the binding specificity of relatively common HLA-I alleles may be as important as expanding allele coverage to rare alleles for neo-antigen discovery.

All HLA peptidomics datasets used in this work were generated with only 1% FDR and are of high purity. For this reason, and also to prevent including potential biases or removing important data, we decided not to filter our data with existing HLA-I ligand predictors, but we expect some contaminants in our large sets of peptides. Moreover, in a few cases, the motifs for some alleles were not detectable (see HLA-C12:03 in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}). This suggests that the (few) peptides binding to this allele may contaminate the other motifs. This is a known situation when analysing HLA peptidomics data with unsupervised approaches \[[@pcbi.1005725.ref024],[@pcbi.1005725.ref025],[@pcbi.1005725.ref046]\]. As previously observed, it affects especially HLA-C alleles which are often poorly expressed and whose binding specificities are more redundant \[[@pcbi.1005725.ref024],[@pcbi.1005725.ref047]\]. However, our results show that some level of noise is tolerated for training our predictor and can still lead to improvement over existing tools ([Fig 4](#pcbi.1005725.g004){ref-type="fig"} and Fig L in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). We also stress that no existing HLA-ligand interaction dataset used for training predictors is free of false-positives and for many alleles the number of ligands is significantly lower (Fig E in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

In a few cases, the motifs of two alleles could not be split because of the very high binding specificity similarity of these alleles (e.g., HLA-C07:01 and HLA-C07:02 in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}). We emphasize that this does not preclude the use of HLA peptidomics data for training HLA-I ligand predictors, since many other samples in our dataset contained only one of these two alleles together with other non-overlapping ones. As such our strategy takes advantage of our large collection of HLA peptidomics datasets to naturally overcome cases where the deconvolution could not be fully achieved in one given sample.

Direct identification of neo-antigens with MS shows higher specificity compared to our predictions based on exome sequencing data \[[@pcbi.1005725.ref016],[@pcbi.1005725.ref017]\], as expected. However, it is important to realize that these experiments are challenging and can be carried out only in a small subset of patients with enough tumor material. Moreover, in many cases, no neo-antigen is found by MS. As such, our work provides a scalable approach to capitalize on large MS data obtained from some patients or cell lines in order to improve predictions of neo-antigens in other patients where MS analysis of the immunopeptidome could not be carried out and only exome sequencing data are available. This work may also find applications in other jawed vertebrate species where reference motifs for MHC-I alleles are poorly described, since the only requirement of our approach is the availability of MHC-I specific antibodies and MHC typing information.

Previous computational approaches for neo-antigen predictions have shown that incorporation of gene expression data could improve accuracy \[[@pcbi.1005725.ref031],[@pcbi.1005725.ref048]\]. Considering that our predictor using only exome sequencing information (i.e., the list of somatic mutations) already enabled us to improve predictions in the cancer samples analysed in this work, we anticipate that integrating additional information such as gene expression, when available, may lead to even more accurate predictions of neo-antigens.

Results shown in [Fig 5](#pcbi.1005725.g005){ref-type="fig"} further emphasize the power of in-depth sampling of the HLA-I ligand space to inform us about molecular mechanisms underlying HLA-I binding properties \[[@pcbi.1005725.ref049]\]. Considering the rapid expansion of HLA peptidomics experiments performed in cancer immunotherapy research \[[@pcbi.1005725.ref013],[@pcbi.1005725.ref017],[@pcbi.1005725.ref018],[@pcbi.1005725.ref020],[@pcbi.1005725.ref027],[@pcbi.1005725.ref028]\], we anticipate that our approach for HLA-I motif identification and annotation will enable similar analyses in the future to uncover other molecular determinants of HLA-I binding specificity.

Overall, our work shows for the first time that HLA-I motifs can be reliably identified across in-depth and accurate HLA peptidomics datasets without relying on HLA-I interaction prediction tools or *a priori* knowledge of HLA-I binding specificity. This unsupervised and scalable approach refines known HLA-I binding motifs and expands our understanding of HLA-I binding specificities to a few additional alleles without documented ligands. As such, this work is a powerful alternative to synthesizing every peptide for *in vitro* binding assays, or to genetically modifying \[[@pcbi.1005725.ref031]\] or transfecting cell lines with soluble HLA-I alleles \[[@pcbi.1005725.ref034],[@pcbi.1005725.ref035],[@pcbi.1005725.ref050]\], and may save substantially amount of money and time for HLA-I motif determination. Our results further contribute to our global understanding of HLA-I binding properties and improve neo-antigen predictions from exome sequencing data. This work may therefore facilitate identification of clinically relevant targets for cancer immunotherapy, especially when direct identification of neo-antigens with MS cannot be experimentally done.

Methods {#sec011}
=======

Ethics statement {#sec012}
----------------

Informed consent of the participants was obtained following requirements of the institutional review board (Ethics Commission, University Hospital of Lausanne (CHUV)).

Cell lines and antibodies {#sec013}
-------------------------

We carefully selected ten donors expressing a broad range of HLA-I alleles and generated novel HLA peptidomics data (Table A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). EBV-transformed human B-cell lines CD165, GD149, PD42, CM467, RA957 and MD155 were maintained in RPMI 1640 + GlutaMAX medium (Gibco, Paisley, UK) supplemented with 10% FBS (Gibco) and 1% Penicillin/Streptomycin Solution (BioConcept, Allschwil, Switzerland). TIL were expanded from two melanoma tumors following established protocols \[[@pcbi.1005725.ref051],[@pcbi.1005725.ref052]\]. Informed consent of the participants was obtained following requirements of the institutional review board (Ethics Commission, University Hospital of Lausanne (CHUV)). Briefly, fresh tumor samples were cut in small fragments and placed in 24-well plate containing RPMI CTS grade (Life Technologies Europe BV, Switzerland), 10% Human serum (Valley Biomedical, USA), 0.025 M HEPES (Life Technologies Europe BV, Switzerland), 55 μmol/L 2-Mercaptoethanol (Life Technologies Europe BV, Switzerland) and supplemented with a high concentration of IL-2 (Proleukin, 6,000 IU/mL, Novartis, Switzerland) for three to five weeks. Following this initial pre-REP, TIL were then expanded in using a REP approach. To do so, 25 x10^6^ TIL were stimulated with irradiated feeder cells, anti-CD3 (OKT3, 30 ng/mL, Miltenyi biotech) and high dose IL-2 (3,000 IU/mL) for 14 days. The final cell product was washed and prepared using a cell harvester (LoVo, Fresenius Kabi). Leukapheresis samples (Apher1 and 6) were obtained from blood donors from the *Service régional vaudois de transfusion sanguine*, *Lausanne*. Upon receival of TIL and leukapheresis samples, the cells were washed with PBS on ice, aliquoted and stored as dry pellets at -80°C until use. High resolution 4-digit HLA-I typing was performed at the Laboratory of Diagnostics, Service of Immunology and Allergy, CHUV, Lausanne.

W6/32 monoclonal antibodies were purified from the supernatant of HB95 cells grown in CELLLine CL-1000 flasks (Sigma-Aldrich, Missouri, USA) using Protein-A Sepharose (Invitrogen, California, USA).

Purification of HLA-I complexes {#sec014}
-------------------------------

We extracted the HLA-I peptidome from 2--5 biological replicates per cell line or patient material. The cell counts ranged from 1 x 10^8^ to 3 x 10^8^ cells per replicate. Lysis was performed with 0.25% sodium deoxycholate (Sigma-Aldrich), 0.2 mM iodoacetamide (Sigma-Aldrich), 1 mM EDTA, 1:200 Protease Inhibitors Cocktail (Sigma, Missouri, USA), 1 mM Phenylmethylsulfonylfluoride (Roche, Mannheim, Germany), 1% octyl-beta-D glucopyranoside (Sigma) in PBS at 4°C for 1 hr. The lysates were cleared by centrifugation with a table-top centrifuge (Eppendorf Centrifuge 5430R, Schönenbuch, Switzerland) at 4°C at 14200 rpm for 20 min. Immuno-affinity purification was performed by passing the cleared lysates through Protein-A Sepharose covalently bound to W6-32 antibodies. Affinity columns were then washed with at least 6 column volumes of 150 mM NaCl and 20 mM Tris HCl (buffer A), 6 column volumes of 400 mM NaCl and 20 mM Tris HCl and lastly with another 6 column washes of buffer A. Finally, affinity columns were washed with at least 2 column volumes of 20 mM Tris HCl, pH 8. HLA-I complexes were eluted by addition of 1% trifluoroacetic acid (TFA, Merck, Darmstadt, Switzerland) for each sample.

Purification and concentration of HLA-I peptides {#sec015}
------------------------------------------------

HLA-I complexes with HLA-I peptides were loaded on Sep-Pak tC18 (Waters, Massachusetts, USA) cartridges which were pre-washed with 80% acetonitrile (ACN, Merck) in 0.1% TFA and 0.1% TFA only. After loading, cartridges were washed twice with 0.1% TFA before separation and elution of HLA-I peptides from the more hydrophobic HLA-I heavy chains with 30% ACN in 0.1% TFA. The HLA-I peptides were dried using vacuum centrifugation (Eppendorf Concentrator Plus, Schönenbuch, Switzerland) and re-suspended in a final volume of 12 uL 0.1% TFA. For MS analysis, we injected 5 uL of these peptides per run.

LC-MS/MS analysis of HLA-I peptides {#sec016}
-----------------------------------

Measurements of HLA-I peptidomics samples were acquired using the nanoflow UHPLC Easy nLC 1200 (Thermo Fisher Scientific, Germering, Germany) coupled online to a Q Exactive HF Orbitrap mass spectrometer (Thermo Fischer Scientific, Bremen, Germany) or with Dionex Ultimate RSLC3000 nanoLC (Thermo Fischer Scientific, *Sunnyvale*, *CA)* coupled online to an Orbitrap Fusion Mass Spectrometer (Thermo Fischer Scientific, San Jose, CA), both with a nanoelectrospray ion source. We packed an uncoated PicoTip 8μm tip opening with diameter of 50 cm x 75 um with a ReproSil-Pur C18 1.9 μm particles and 120 Å pore size resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) re-suspended in Methanol. The analytical column was heated to 50°C using a column oven. Peptides were eluted with a linear gradient of 2--30% buffer B (80% ACN and 0.1% formic acid) at a flow rate of 250 nl/min over 90 min.

Data was acquired with data-dependent "top10" method, which isolates the ten most intense ions and fragments them by higher-energy collisional dissociation (HCD) with a normalized collision energy of 27% and 32% for the Q Exactive HF and Fusion instruments, respectively. For the Q Exactive HF instrument the MS scan range was set to 300 to 1,650 *m/z* with a resolution of 60,000 (200 *m/z*) and a target value of 3e6 ions. The ten most intense ions were sequentially isolated and accumulated to an AGC target value of 1e5 with a maximum injection time of 120 ms and MS/MS resolution was 15,000 (200 *m/z*). For the Fusion, a resolution of 120,000 (200 *m/z*) and a target value of 4e5 ions were set. The ten most intense ions accumulated to an AGC target value of 1e5 with a maximum injection time of 120 ms and MS/MS resolution was 15,000 (200 *m/z*). The peptide match option was disabled. Dynamic exclusion of fragmented *m/z* values from further selection was set for 20 or 30 seconds with the Q Exactive HF and Fusion instruments, respectively.

Data analysis of HLA-I peptides {#sec017}
-------------------------------

We employed the MaxQuant computational proteomics platform \[[@pcbi.1005725.ref039]\] version 1.5.3.2 to search the peak lists against the UniProt databases (Human 85,919 entries, May 2014) and a file containing 247 frequently observed contaminants. N-terminal acetylation (42.010565 Da) and methionine oxidation (15.994915 Da) were set as variable modifications. The second peptide identification option in Andromeda was enabled. A false discovery rate of 0.01 was required for peptides and no protein false discovery rate was set. The enzyme specificity was set as unspecific. Possible sequence matches were restricted to 8 to 15 amino acids, a maximum peptides mass of 1,500 Da and a maximum charge state of three. The initial allowed mass deviation of the precursor ion was set to 6 ppm and the maximum fragment mass deviation was set to 20 ppm. We enabled the 'match between runs' option, which allows matching of identifications across different replicates of the same biological sample in a time window of 0.5 min and an initial alignment time window of 20 min.

Publicly available HLA peptidomics data {#sec018}
---------------------------------------

To expand the number of samples and survey an even broader range of HLA-I alleles, we included in this study forty publicly available HLA peptidomics data from seven recent studies \[[@pcbi.1005725.ref017],[@pcbi.1005725.ref018],[@pcbi.1005725.ref022],[@pcbi.1005725.ref023],[@pcbi.1005725.ref026]--[@pcbi.1005725.ref028]\]. Only samples with HLA-I typing were used. Peptides identified in the recent study \[[@pcbi.1005725.ref018]\] in different repeats and under different treatments were pooled together to generate one list of unique peptides per sample. Since the published peptidomics datasets from Pearson et al. \[[@pcbi.1005725.ref028]\] were filtered to include only peptides with predicted affinity scores of less or equal to 1250 nM, we re-processed the mass spectrometer raw data using MaxQuant with similar settings as mentioned above except that peptide length was set to 8--25 mers ([S2 Dataset](#pcbi.1005725.s003){ref-type="supplementary-material"}). HLA typing information was retrieved from the original publications. In one case (THP-1 cell lines), the typing is controversial \[[@pcbi.1005725.ref053]\]. In this work, we used the typing determined by the authors of the HLA peptidomics study where the data came from \[[@pcbi.1005725.ref023]\]. The high fraction (\>50% of the peptides) displaying a clear A24:02 and B35:03 motif based on our unsupervised deconvolution further indicates that these alleles are truly expressed in the sample on which the HLA peptidomics analysis was performed.

IEDB data {#sec019}
---------

Known HLA-I ligands were retrieved from IEDB (mhc_ligand_full.csv file, as of Oct 2016) \[[@pcbi.1005725.ref004]\]. All ligands annotated as positives with a given HLA-I allele (i.e., "Positive-High", "Positive-Intermediate", "Positive-Low" and "Positive") were used to build the IEDB reference motifs ([Fig 2A and 2C](#pcbi.1005725.g002){ref-type="fig"}). Ligands coming from HLA peptidomics studies analysed in this work were not considered to prevent circularity in the motif comparisons and because the HLA-I alleles to which these peptides bind were not experimentally determined. Position Weight matrices (PWMs) representing binding motifs in IEDB and used to compare with motifs derived from our deconvolution of HLA peptidomics datasets were built by computing the frequency of each amino acid at each position and using a random count of 1 for each amino acid at each position.

HLA peptidomics data from mono-allelic cell lines {#sec020}
-------------------------------------------------

All 16 HLA peptidomics datasets obtained from mono-allelic cell lines were downloaded from \[[@pcbi.1005725.ref031]\]. Motifs used in the comparison presented in [Fig 2B](#pcbi.1005725.g002){ref-type="fig"} were built in the same way as for IEDB data. When benchmarking our ability to re-predict such data with, we considered 9-mers from the ten alleles that overlapped our set of deconvoluted HLA peptidomics data and added 99-fold excess of random peptides from the human proteome. The fraction of positives (i.e., MS peptides identified in these mono-allelic cell lines) predicted in the top 1% was used to assess the prediction accuracy with different methods. Peptides with a clear tryptic peptide signature (i.e., R/K at the last position for all alleles except HLA-A03:01 and HLA-A31:01) were manually removed.

Mixture model for HLA-I binding motifs identification in HLA peptidomics data {#sec021}
-----------------------------------------------------------------------------

An algorithm based on mixture models and initially developed for multiple specificity analysis in peptide ligands \[[@pcbi.1005725.ref029],[@pcbi.1005725.ref030]\] was used to identify binding motifs in each dataset analysed in this work. Briefly, all peptides pooled by mass spectrometry analysis of eluted peptide-HLA-I complexes in a given sample were first split into different groups according to their size (9--10 mers). All 9- and 10-mers ligands were then modelled using multiple PWMs \[[@pcbi.1005725.ref024]\]. The results of such analysis consist of a set of PWMs that describe distinct motifs for each HLA peptidomics datasets (see Fig A in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) and probabilities (i.e., responsibilities) for each peptide to be associated with each motif. Sequence logos representing HLA-I motifs were generated with the LoLa software (<http://baderlab.org/Software/LOLA>). The command-line script for the mixture model ("MixMHCp") can be downloaded at: <https://github.com/GfellerLab/MixMHCp>.

Fully unsupervised deconvolution of HLA peptidomics datasets {#sec022}
------------------------------------------------------------

The availability of high-quality HLA peptidomics data from several samples with diverse HLA-I alleles suggest that one could infer which motifs correspond to which HLA-I alleles without relying on comparison with known motifs. For instance, if two samples share exactly one HLA-I allele, it is expected that the shared motif will originate from the shared allele ([Fig 1](#pcbi.1005725.g001){ref-type="fig"}). To exploit this type of patterns of shared HLA-I alleles, we designed the following algorithm:

1.  For each allele present in at least two samples, find all samples that share this allele (e.g., HLA-A24:02 in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}). Identify the shared motif. If a shared motif is found, map this motif to the corresponding allele in each sample.

2.  Find samples that share all except one allele with another sample (Fig B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). Find the motif that is not shared and map it to the HLA-I allele that is not shared.

3.  Check if some samples contain exactly one motif and one allele that have not yet been associated. Annotate the remaining motif to the corresponding allele.

4.  Use the motifs mapped to HLA-I alleles in steps 1), 2) and 3) to identify them in other samples that contain these alleles based on motif similarity.

5.  Go back to 1) until no new motif can be mapped to HLA-I alleles.

Comparison of motifs was performed using (squared) Euclidean distance between the corresponding PWMs: $D^{2} = \frac{1}{L}\sum_{i = 1}^{20}{\sum_{A = 1}^{L}\left( {M_{iA} - M_{iA}^{\prime}} \right)^{2}}$, where *M* and *M'* stands for two PWMs (i.e., *20* x *L* matrices) to be compared and *L* is the peptide length. A threshold of *T* = 0.078 was used to define similar motifs based on visual inspection of the results. Cases of inconsistencies (i.e., distances larger that T) between motifs mapped to the same allele were automatically eliminated. The final binding motif for each HLA-I allele ([Fig 2](#pcbi.1005725.g002){ref-type="fig"} and Fig D in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) was built by combining peptides from each sample that had been associated with the corresponding allele. Other measures of similarity between PWMs \[[@pcbi.1005725.ref033]\] did not improve the results (see for instance comparison between Euclidean distance and Jensen-Shannon divergence in Fig Q in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} for the example shown in [Fig 1](#pcbi.1005725.g001){ref-type="fig"}) and we therefore used the Euclidean distance throughout this study. To further study the statistical significance of the similarity between motifs annotated to the same alleles, we computed the P-value of the similarity for each pair of motifs annotated to the same allele. To this end, we used both the Euclidean distance and the BLiC score with standard Dirichlet priors and hyper-parameters α~j~ (*j* = 1...20) equal to one, as introduced in ref. \[[@pcbi.1005725.ref033]\]. This BLiC score was re-implemented using 20 amino acids (instead of the 4 nucleotides) and the background distribution was taken as the expected amino acid frequencies in MS data (see Table B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). For a pair of motifs (*m*~*i*~, *m*~*j*~), empirical P-values were estimated by comparing the similarity between motifs *m*~*i*~ and *m*~*j*~ to the similarity between motif *m*~*i*~ and all known HLA-I motifs (i.e, 107 in total, taking only alleles with more than 20 unique ligands in IEDB and excluding the allele to which the motif *m*~*i*~ had been annotated). The distributions of P-values for all pairs of motifs annotated to the same alleles (i.e., for each allele *h*, *i = 1*, *...N*~*h*~, *j = 1...N*~*h*~, with *i≠j* and *N*~*h*~ the number of motifs annotated to allele *h*) are shown in Fig G in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} for both the Euclidean distance and the BLiC score \[[@pcbi.1005725.ref033]\], and indicate that for more than 99% of the pairs of motifs annotated to the same alleles, the similarity has a P-value smaller than 0.05. The few pairs with P-values larger than 0.05 come mainly from HLA-C allele, as expected since they are less expressed and more degenerate, and therefore more challenging to describe.

We further studied the impact of the threshold T and explored several values between 0.01 and 0.14. As shown in Fig H in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}, smaller values of T result in fewer alleles to which motifs can be annotated, as expected. Reversely, for larger thresholds the algorithm seems to behave badly and many more motifs annotated to the same alleles are no longer statistically similar. Data in Fig H in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} suggest that reasonable results can be obtained for thresholds between 0.05 and 0.09, which is compatible with our manual choice of 0.078.

In practice, HLA-A and HLA-B alleles tend to be more expressed and therefore give rise to a stronger signal in HLA peptidomics data. We therefore used first our deconvolution method \[[@pcbi.1005725.ref024]\], setting the number of motifs equal to the number of HLA-A and HLA-B alleles and identified HLA-A and HLA-B motifs with the algorithm introduced above (Step 1). We then ran our deconvolution method \[[@pcbi.1005725.ref024]\] without restricting the number of clusters (Step 2) and identified motifs corresponding to HLA-A and HLA-B alleles based on the similarity with those identified in Step 1. The remaining motifs were then analysed across all samples with the algorithm introduced above.

Semi-supervised deconvolution of HLA peptidomics datasets {#sec023}
---------------------------------------------------------

To expand the identification of binding motifs for alleles without known ligands, we used data from IEDB for HLA-I alleles with well-described binding motifs. In practice, for all HLA-I alleles in our samples that had not been mapped to motifs in the fully unsupervised approach and have more than twenty different ligands in IEDB, PWMs were built from IEDB data. These PWMs were used to scan the remaining motifs in each sample that contained the corresponding alleles. Motifs were mapped to HLA-I alleles if exactly one PWM obtained with the mixture model was found to be similar to the IEDB-derived motif (i.e., Euclidean distance smaller than T, as before). The unsupervised procedure described above was then applied to the remaining motifs to identify new motifs for alleles without ligands in IEDB.

Amino acid frequencies at non-anchor positions in HLA peptidomics datasets {#sec024}
--------------------------------------------------------------------------

To have reliable estimates of the potential technical biases due to MS, amino acid frequencies were computed at non-anchor positions (P4 to P7) for alleles in our HLA peptidomics datasets (9-mers). Alleles showing some specificity at these positions (A02:01, A02:05, A02:06, A02:20, A25:01, A26:01, A29:02, B08:01, B14:01, B14:02, C03:03, and C07:04, see Fig D in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}) were excluded from this analysis. The average frequencies of amino acids across alleles were then compared against the human proteome using Pearson correlation coefficient ([Fig 3](#pcbi.1005725.g003){ref-type="fig"}). We also performed the same analysis with HLA-I ligands (9-mers) from IEDB splitting between those obtained by MS and those obtained by other assays ("non-MS data") (see Fig J in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). To enable meaningful comparison between these datasets, only alleles present in our HLA peptidomics data, with more than 100 ligands in both IEDB MS and non-MS data were considered in this analysis (14 alleles in total, see Fig D in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

Prediction of neo-antigens {#sec025}
--------------------------

For each HLA-I allele, PWMs were built from all peptides associated to this allele across all samples where the binding motif could be identified, using the highest responsibility values of the mixture model \[[@pcbi.1005725.ref024]\]. The frequency of each amino acid was first computed. Pseudocounts were added using the approach described in \[[@pcbi.1005725.ref054]\], based on the BLOSUM62 substitution matrix with parameter β = 200. The score of a given peptide (*X*~*1*~, ...*X*~*N*~) was computed by summing the logarithm of the corresponding PWM entries, including renormalization by expected amino acid frequencies: $S = \frac{1}{N}\sum_{i = 1}^{N}{\text{log}(\frac{p_{X_{i},i}}{q_{X_{i}}})}$. Here *q*~*A*~ stands for frequency of amino acid A at non-anchor positions ([Fig 3](#pcbi.1005725.g003){ref-type="fig"} and Table B in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}), *p*~*A*,\ *i*~ stands for the PWM entry corresponding to amino acid *A* at position *i*, and *N* stands for the length of the peptide (*N* = 9, 10). The final score of a peptide was taken as the maximal score across all alleles present in a given sample and a P-value estimate is computed by comparing with distribution of scores obtained from 100,000 randomly selected peptides from the human proteome, so as to have similar amino acid frequencies compared to endogenous ligands (see MixMHCpred1.0 results).

To test our ability to predict neo-antigens, we used four melanoma samples in which ten neo-antigens (9- and 10-mers) have been directly identified with in-depth immunopeptidomics analyses of the tumor samples: Mel5, Mel8, Mel15 from \[[@pcbi.1005725.ref017]\] and 12T \[[@pcbi.1005725.ref020]\]. Missense mutations (i.e. cancer specific non-synonymous point mutations) identified by exome sequencing in those four melanoma samples \[[@pcbi.1005725.ref017]\] were retrieved and a list of all possible 9- and 10-mer peptides encompassing each mutation was built ([S3 Dataset](#pcbi.1005725.s004){ref-type="supplementary-material"}). Multiple transcripts corresponding to the same genes were merged so that each mutated peptide appears only once in the list. The total number of potential neo-antigens in each sample is shown in [Table 1](#pcbi.1005725.t001){ref-type="table"}. Predictions for each HLA-I allele of each sample were carried out with the model described above. Peptides were ranked based on the highest score over the different alleles present in their sample. In parallel, affinity predictions with NetMHC (v4.0) \[[@pcbi.1005725.ref008]\] and NetMHCpan (v3.0) \[[@pcbi.1005725.ref012]\] and stability predictions with NetMHCstabpan (v1.0) \[[@pcbi.1005725.ref036]\] were performed for the same peptides and peptides were ranked based on predicted affinity using the highest score (i.e., lowest Kd) over all alleles. Only HLA-A and HLA-B alleles were considered since HLA-C alleles are known to show much lower expression and both our predictor and NetMHC could not be run for some HLA-C alleles in these melanoma patients. Ranking of the neo-antigens compared to all possible peptides containing a missense mutation is shown in [Table 1](#pcbi.1005725.t001){ref-type="table"} with either our predictor (MixMHCpred) or the other tools mentioned above. Area Under the Curves were also computed ([Fig 4B](#pcbi.1005725.g004){ref-type="fig"}), as well as the fraction of neo-antigens that fell among the top 1% of the predictions (PP1%, which typically corresponds to what can be experimentally tested) ([Fig 4C](#pcbi.1005725.g004){ref-type="fig"}), to provide a graphical visualization of the results in [Table 1](#pcbi.1005725.t001){ref-type="table"}.

The same analysis was applied to study neo-antigens (9- and 10-mers) recently identified in two lung cancer patients \[[@pcbi.1005725.ref037]\] (L011: FAFQEYDSF, GTSAPRKKK, SVTNEFCLK, RSMRTVYGLF, GPEELGLPM and L013: YSNYYCGLRY, ALQSRLQAL, KVCCCQILL) and the ranking of these epitopes with different HLA-ligand predictors with respect to the full list of potential epitopes is shown in Table C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"} (see also [Fig 4B and 4C](#pcbi.1005725.g004){ref-type="fig"}).

Predictions of neo-antigens in melanoma samples---Cross-patient validation {#sec026}
--------------------------------------------------------------------------

To assess how much our improved predictions of neo-antigens in the three melanoma samples of \[[@pcbi.1005725.ref017]\] depend on HLA peptidomics data generated from these samples, we performed a careful cross-sample validation. For each of the three samples where neo-eptiopes had been identified (Mel15, Mel8, Mel5) \[[@pcbi.1005725.ref017]\], we re-run our entire pipeline (i.e., annotation of HLA-I motifs across HLA peptidomics datasets + construction of PWMs for each allele) without the HLA peptidomics data coming from this sample. The PWMs were then used to rank all possible peptides (9- and 10-mers) encompassing each mutation. Overall, the predictions changed very little (Fig K in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}).

Predictions of cancer testis antigens {#sec027}
-------------------------------------

All cancer testis antigens with annotated epitopes (9- or 10-mers) and HLA restriction information were retrieved from the CTDatabase \[[@pcbi.1005725.ref038]\] for all alleles considered in our predictor (see Table C in [S1 Supporting Information](#pcbi.1005725.s001){ref-type="supplementary-material"}). All other possible peptides along these proteins (9- or 10-mers) were used as negatives when benchmarking the predictions on this dataset.

Analysis of HLA sequences and structures {#sec028}
----------------------------------------

HLA-I sequences were retrieved from IMGT database \[[@pcbi.1005725.ref003]\]. All protein structures analysed in this work were downloaded from the PDB. Residues forming the P2 binding site in HLA-B14:02 (PDB: 3BVN \[[@pcbi.1005725.ref042]\]) were determined using a standard cut-off of 5Å from any heavy atoms of arginine at P2.

Binding stability assays for HLA-B14:02 wt and W97R mutant {#sec029}
----------------------------------------------------------

W97R mutation was introduced into HLA-B14:02 wt by overlap extension PCR and confirmed by DNA sequencing. BL21(DE3)pLys bacterial cells were used to produce HLA-B14:02 wt and W97R as inclusion bodies. Four peptides with histidine or arginine at P2 (A\[H/R\]TKPRPAL, G\[H/R\]YDRSKSL, A\[H/R\]FAKSISL, H\[H/R\]FEKAVTL) were synthesized at the Peptide Facility (UNIL, Lausanne) with free N and C-termini (1mg of each peptide, \> 80% purity). Peptides with histidine at P2 come from our HLA peptidomics data and were assigned to HLA-B15:18 by our mixture model algorithm. Based on our analysis of HLA sequence and structure, peptides with histidine at P2 are predicted to interact with HLA-B14:02 W97R, while peptides with arginine at P2 are predicted to bind better HLA-B14:02 wt.

Synthetic peptides were incubated separately with denaturated HLA-B14:01 wt and HLA-B14:01 W97R mutant refolded by dilution in the presence of biotinylated beta-2 microglobulin proteins at temperature T = 4°C for 48 hours. The solution was then incubated at 37°C and samples were retrieved at time t = 0h, 8h, 24h, 48h and t = 72h. The known HLA-B14:02 ligand IRHENRMVL was used for positive controls. Negative controls consist of absence of peptides. k~off~ were determined by fitting exponential curves to the light intensity values obtained by ELISA at different time points. Half-lives were computed as ln(2)/k~off~. Values shown in [Fig 5D](#pcbi.1005725.g005){ref-type="fig"} correspond to the average over two replicates. For two peptides showing exceptionally high binding stability, only lower bounds on half-lives could be determined (dashed lines in [Fig 5D](#pcbi.1005725.g005){ref-type="fig"}).

Supporting information {#sec030}
======================

###### Supplementary figures and tables.

(PDF)

###### 

Click here for additional data file.

###### List of peptides identified in the ten new HLA peptidomics datasets generated in this work.

(ZIP)

###### 

Click here for additional data file.

###### List of peptides reprocessed from Pearson et al. \[[@pcbi.1005725.ref028]\] without any filtering based on predicted affinity.

(ZIP)

###### 

Click here for additional data file.

###### List of potential neo-antigens (i.e. peptides encompassing a missense mutation) from exome sequencing data of four melanoma samples \[[@pcbi.1005725.ref017],[@pcbi.1005725.ref020]\] analyzed in this work together with the score for the different alleles according to our predictor and other HLA-I ligand prediction tools.

(ZIP)

###### 

Click here for additional data file.
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